reason report
morphosi deal diversifi rev net neutral impact pt
bottom line follow announc global collabor deal
morphosi mor gy op cover geoffrey porg see initi
take-away updat model incorpor us/
eu forecast revenu tafasitamab tafa r/r diffus larg b-
cell lymphoma dlbcl includ financi term global
collabor favor aspect deal includ give incyt
access tafasitamab potenti best-in-class antibodi
partial diversifi revenu away backbon jakafi franchis
face ip expiri help justifi commerci
infrastructur europ built larg anticip
epacadostat launch howev continu see deal lack
transform aspect mani investor hope see
extend jakafi franchis ip anticip tafasitamab revenu
partial off-set expect impact patent cliff
tafasitamab promis drug dlbcl extrem dynam
competit therapeut area mani differ class drug
impact evolv treatment paradigm net impact deal
pt neutral anticip tafasitamab revenu profit
off-set larg up-front payment gener royalti stream equiti
stake made secur deal reiter mp rate
updat model reflect deal neutral impact
valuat follow announc morphosi collabor
deal financi term incorpor tafa model
assum us launch r/r dlbcl peak revenu
assign probabl success
program result risk-adjust npv
also assum eu launch tafa r/r dlbcl given guidanc
ema submiss plan peak revenu
pay estim tier
royalti eu sale assign probabl success
program result risk-adjust npv
notabl model tafa revenu asian territori
japan china leav region upsid also
explicitli model tafa expans indic follicular
lymphoma fl margin zone lymphoma mzl chronic lymphocyt
leukemia cll lastli broadli updat model reflect
up-front fee equiti invest approv
mileston expect occur next month net
model chang result chang pt
net debt total capit
price-to-earnings lt ep growth
net debt total capit calcul use bv
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep
pleas refer page import disclosur price chart analyst certif
rate corp share market perform pt commerci stage
biotechnolog compani develop drug modul pathway involv cell signal
oncolog autoimmun disord compani solid backbon revenu lead
asset jakafi oral inhibitor jak pathway estim worth per share
howev see compani execut goal diversifi revenu see stock
fulli valu favor upcom catalyst potenti competit fedratinib gener
eros anticip promis asset pipelin think
opportun alreadi larg reflect share howev share could repres
good invest investor longer term horizon beyond one year valuat
will invest mid-cap biotechnolog compani solid financi fundament
updat model incorpor tafasitamab deal
maintain pt
updat model follow global collabor morphosi lead asset
tafasitamab updat leverag svb leerink us/eu forecast tafasitamab
revenu relapsed/refractori diffus larg b-cell lymphoma dlbcl estim
oper expens well announc financi term
us morphosi co-promot tafa morphosi lead
commerci strategi book revenu morphosi share profit
loss basi tafa bla submiss decemb potenti approv
model initi commerci us gradual uptak result
peak revenu assign probabl success result
risk-adjust npv per share eu exclus
commerci right lead commerci strategi cover develop cost
book revenu pay morphosi tier royalti mid-teen mid-twenti
percentag net sale submiss market author applic eu
plan model initi launch eu peak revenu
achiev assign probabl success result risk-
adjust npv overal aggreg risk-adjust npv tafasitamab
revenu per share
current includ asian revenu tafa model leav potenti
upsid also includ potenti expans opportun tafa b-cell
malign includ frontlin dlbcl fl mzl cll leav upsid
lastli incorpor up-front fee equiti invest
potenti near-term regulatori mileston payment increas forecast
oper expens support clinic develop commerci assum
paid well regulatori mileston payment morphosi
next month assumpt result net cash balanc
anticip residu cash prior chang
neutral impact pt maintain pt
use risk-adjust sum-of-the-part methodolog valu examin clinic
regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev revenues/
expens risk-adjust sum-of-the-part analysi appli discount rate cash
flow gener asset determin total net present valu risk-
adjust asset total npv reflect remain clinic regulatori risk program
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current value/sharejakafi polycythemia eu us ra eu ra ad indic inhibit fgfr fl mcl cmet ww jak atop jak us r/r regulatori eu r/r oncolog pipelinei ii asset share count total risk-adjust equiti valu risk residu non-deplet profitabilityincyt corpor mf/pvolumianticlusigjak jaktafasitamab dlbclearli oncolog pipelin te corpor
commerci risk competit compani develop treatment myelofibrosi
polycythemia vera therapeut area compet repres risk
clinic risk clinic trial failur incyt compound develop includ itacitinib
pemigatinib ruxolitinib compani earli stage pipelin repres risk
current valuat
regulatori risk even posit clinic data regulatori approv need market
prescript drug develop market regul may declin approv applic
incyt development-stag compound repres risk current valuat
companyprogram/drugtherapeut areaeventtimingev typetri phaseincytetop ruxolitinibatop dermatitisdata phiii true-ad trial topic ruxolitinib mild-moder trial dataphiiiincytejakafigraft vs host diseasedata phiii trial steroid refractori chronic trial dataphiiiincytepemigatinibcholangiocarcinomapotenti us approv cholangiocarcinoma may tafasitamabdiffus larg cell lymphoma potenti approv r/r dlbcl lymphomapotenti data phii r/r trial zone lymphomapotenti data phii r/r trial cell lymphomapotenti data phii r/r trial lymphomapotenti nda submiss r/r fl base data phii zone lymphomapotenti nda submiss r/r mzl base data phii cell lymphomapotenti nda submiss r/r mcl base data phii cancerpotenti nda submiss bladder cancer base vs host diseasepotenti snda file steroid refractori gvhd base cancerdata phii trial high r/r endometri trial cell carcinomadata phii tiral merkel cell trial cancerdata phii trial r/r anal trial cancerpotenti bla file endometri cell carcinomapotenti bla file merkel cell cancerpotenti bla file anal vs host diseasedata trial chronic trial dataphiiiincyt catalyst corpor
 mn except ep
product revenu
chang fair valu acquisition-rel conting consider
earn tax ebt
balanc sheet mn
compani report svb leerink estim
